证券代码：603983 证券简称：丸美股份 公告编号：2024-048 广东丸美生物技术股份有限公司 控股股东及实际控制人减持计划时间届满暨 未减持股份的结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 大股东持股的基本情况 截至本减持计划披露前，广东丸美生物技术股份有限公司（以下简称"公司"） 控股股东、实际控制人、董事长兼首席执行官孙怀庆先生持有公司 291,600,000 股，占公司总股本的 72.72%。 减持计划的实施结果情况 因自身资金需求，孙怀庆先生计划在 2024 年 8 月 26 日至 2024 年 11 月 25 日期间，采用集中竞价及大宗交易的方式减持公司股份数量合计不超过 12,030,000 股，不超过公司总股本的 3%。其中，通过集中竞价交易方式进行减 持的，任意连续 90 日内减持总数不超过公司股份总数的 1%；通过大宗交易方式 进行减持的，任意连续 90 日内减持总数不超过公司股份总数的 2%。详见公司于 2024 年 8 月 1 日披露的《广东丸美生物技术股份 ...

各位投资人大家这个上午好那很高兴大家能够参加我们这次完美股份的一个交流我是国源商社首席理点那么今天我们非常荣幸的邀请到了完美股份的董立成总给大家就公司的一个情况做一个交流那么从公司披露的三级报大家也能看到整体在整个消费承压的情况下完美的业绩表现还是非常超预期的 那么在过去的双十一的表现当中我们也能看到不管是天猫还是抖音平台从低翻光数据上都能感受到完美整体还是有取得了比这个行业大盘更为亮眼突出的一个表现那么我想会议今天分成两个部分第一个部分我们首先邀请程总就公司的一些近况给大家做一个更新 以及对于明年从产品渠道营销策略方面还有公司的一些展望第二个部分我们开放问答环节那么首先有请陈总给大家做一个主要的交流有请陈总好的 谢谢各位国人谢谢姚老师的介绍首先就是也欢迎大家参加我们这次的交流 这是如刚刚吴老师所讲的完美组成的话从去年2023年1月1日以来到今年3月1日1月1日是4个月实现了收入和利润上方就是在30左右的一个增长也基本兑现了本土对于整个中产本地产品产品产商市场或者说我们之前做的一些预判的一个 陈总你这边声音稍微有点不是特别清楚稍微有点回声会有一些回声我不知道是您有耳机佩戴还是什么稍微有点 我觉得这一次大家可能 ...

Investment Rating - The report maintains a "Buy" rating for the company [6][5] Core Insights - In Q3 2024, the company achieved revenue of 600 million yuan, representing a year-on-year growth of 25.8%. The net profit attributable to shareholders was 60 million yuan, up 44.3% year-on-year, while the net profit excluding non-recurring items also reached 60 million yuan, reflecting a 56.1% increase [4][5] - The revenue growth accelerated on a quarter-on-quarter basis, with significant improvements in core product categories. For the first three quarters of 2024, the company's revenue grew by 27.1%, with quarterly growth rates of 38.7%, 18.6%, and 25.8% respectively. The core eye care category benefited from the upgrade of the "Little Red Pen" eye cream, showing a notable improvement in growth [4][5] - The company's gross margin in Q3 2024 increased by 2.1 percentage points to 74.5%, attributed to improved product mix and higher average selling prices in skincare, eye care, and cleansing categories. The operating profit margin also saw significant improvement due to optimized expense ratios [5] Summary by Sections Revenue Performance - The company reported a revenue of 600 million yuan in Q3 2024, with a year-on-year increase of 25.8%. The revenue growth for the first three quarters was 27.1%, with Q1, Q2, and Q3 growth rates of 38.7%, 18.6%, and 25.8% respectively. The eye care, skincare, cleansing, and beauty categories achieved revenues of 120 million, 220 million, 50 million, and 200 million yuan, with year-on-year changes of 22.3%, 15.1%, 12.2%, and 54.1% respectively [4][5] Profitability Analysis - The gross margin for Q3 2024 improved to 74.5%, a 2.1 percentage point increase year-on-year. The improvement is attributed to better product mix and increased average selling prices across key categories. The net profit margin for Q3 was 10.4%, up 1.3 percentage points year-on-year [5] Investment Recommendations - The company is currently in a phase of enhancing single product aggregation and increasing single product value, which is driving gross margin improvements. The main brand is seeing significant growth in core single products, particularly in the eye care category, with stable growth in skincare products. The report forecasts EPS for 2024, 2025, and 2026 to be 0.93, 1.21, and 1.57 yuan respectively [5][6]

证券代码：603983 证券简称：丸美股份 公告编号：2024-047 广东丸美生物技术股份有限公司 2024 年前三季度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2024/11/15 | － | 2024/11/18 | 2024/11/18 | 差异化分红送转： 否 无限售条件流通股的红利委托中国结算上海分公司通过其资金清算系统向 股权登记日上海证券交易所收市后登记在册并在上海证券交易所各会员办理了 指定交易的股东派发。已办理指定交易的投资者可于红利发放日在其指定的证券 营业部领取现金红利，未办理指定交易的股东红利暂由中国结算上海分公司保管， 待办理指定交易后再进行派发。 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经公司 2024 年 5 月 17 日的 2023 年年度股东大会授权董 事会决策与实施，无须 ...

Investment Rating - The investment rating for the company is "Add" [4][9]. Core Insights - The company reported a strong performance in Q3 2024, with revenue reaching 1.952 billion yuan, a year-over-year increase of 27.07%, and a net profit of 239 million yuan, up 37.38% year-over-year. Q3 alone saw revenues of 600 million yuan, growing 25.79% year-over-year, and a net profit of 62 million yuan, which is a 44.32% increase year-over-year [1][2]. Revenue Growth by Product Category - All major product categories experienced positive revenue growth, with beauty products showing the most significant increase. In Q3 2024, revenue from eye care, skin care, cleansing, and beauty products reached 124 million, 215 million, 55 million, and 202 million yuan respectively, with year-over-year growth rates of 22.28%, 15.14%, 12.25%, and 54.11% [2]. Profitability Metrics - The gross margin and net margin improved in Q3 2024, with gross margins at 74.52%, up 2.07 percentage points year-over-year, and net margins at 10.46%, an increase of 1.41 percentage points year-over-year. The sales expense ratio slightly decreased year-over-year [2][6]. Future Earnings Forecast - The company is projected to achieve revenues of 2.786 billion yuan in 2024, with a growth rate of 25.20%. The net profit is expected to reach 356 million yuan, reflecting a growth rate of 37.10%. Earnings per share (EPS) are forecasted to be 0.89 yuan [3][6]. Market Performance - The company's stock is currently priced at 31.25 yuan, with a total market capitalization of 12.531 billion yuan [4].

公司报告 | 季报点评 24Q3 归母净利 yoy+44.32%，业绩超预期 公司发布 24 年三季报。24 年 Q1-3 营收 19.52 亿，yoy+27.07%；归母净利 2.39 亿元，yoy+37.38%。24 年 Q3 公司实现营收 6.0 亿，yoy+25.79%，归 母净利 0.62 亿，yoy+44.32%。 ■分业务看，24Q3 单季度眼部类营收 1.2 亿元，同增 22%，护肤类营收 2.2 亿元，同增 15%，洁肤类营收 0.5 亿元，同增 12%，美容类营收 2.0 亿元， 同增 54%。 ■成本&费用，24Q3 累计毛利率 74.63%，同增 3.79pct，主要系产品结构 进一步优化及精益管理所致；24Q3 毛利率 74.52%，同增 2.08pct。24Q3 年销售/管理/研发费用率分别为 58.8%/4.2%/3.2%，yoy-0.3/-1.3/+0.0pct。 公司持续推进降本增效，在保持收入增长同时亦控制好管理费用。 投资建议：公司坚持文化自信、保持战略定力，线上转型突破，持续专注 主业经营，以用户为中心，坚定推行大单品策略，夯实丸美眼部护理专家+ 抗衰老大师品牌心智，渗 ...

广东丸美生物技术股份有限公司 2024 年三季度业绩交流会会议纪要 一、会议召开情况 会议时间：2024 年 10 月 28 日 15:15 召开方式：线上会议 参会人员：董事长兼 CEO 孙怀庆、董事兼 CFO 王开慧、独立董事张启祥、董 事会秘书程迪 主要参会机构：详见"附件：参会机构清单" 二、会议纪要 （一）管理层介绍 2024 年三季度财务情况 营业收入： 2024 年前三季度公司实现营业收入 19.52 亿元，同比增长 27.07%，各品类 收入均实现同步增长，主要是主品牌丸美以及第二品牌 PL 恋火均持续保持了较好 的增长势能。自线上转型以来，公司已连续 7 个季度实现收入和利润双双较好增长。 毛利率： 2024 年前三季度公司整体毛利率 74.63%，同比上升 3.78 个百分点。报告 期内，公司持续推进大单品策略，心智大单品表现较好，产品集中度进一步提升， 货品结构也更加清晰与聚焦；同时，公司坚持效率优先与精细化管理原则，从供应 链到市场运营，推动产销协同，前台、中台、后台资源得以更好的配置，实现降本 增效；加之公司营业收入增长，毛利率水平有效提升。 2023 年公司毛利率 70.69%、2 ...

进入第一个环节为了帮助大家更清晰地了解完美智商的经验下面我们有请董事兼首席财务官王开惠先生为大家解读财务情况有请王总谢谢 各位投资者分析师朋友下午好现在我来做完美股份2024年三季度财务情况的回顾和解读首先我们看一下我们的营业收入2024年前三个季度公司实现营业收入19.52亿元同比增长27.07% 自线上转型以来公司已连续七个季度实现近30%的增长公司营收整体保持增长得益于主品牌完美以及第二品牌PL炼火均保持较好的增长势能毛利率方面2024年前三个季度公司整体的毛利率为74.63% 同比上升3.78个百分点报告其内公司持续推进大单品策略新制大单品表现较好产品集中度进一步提升货品结构也更加清晰和细胶同时公司坚持效率优先以经济化管理原则从供应链到市场运营 推动产销协同前端中台后端资源而以更好的配置实现了降本增效加之公司营业收入增长毛利率水平有效提升2023年公司毛利率为70.69%2024年QE的毛利率为74.61%2024年上半年的毛利率为74.68% 到现在前三个季度整体毛利率为74.63%2024年公司的毛利率水平保持稳健健康的维持向好我们再看一下纪律论和纪律能力2024年前三个季度归属于上市公司普通的纪 ...

Investment Rating - The report maintains a "Buy" rating for the company [5][11]. Core Views - The company reported better-than-expected performance in Q3 2024, with a revenue of 1.95 billion yuan, a year-on-year increase of 27.07%, and a net profit attributable to shareholders of 239 million yuan, up 37.38% year-on-year [3]. - The gross profit margin for the first three quarters was 74.63%, and the net profit margin was 12.23% [3]. - The company is focusing on a big product strategy, enhancing its brand image in the eye care and anti-aging segments, with significant growth in its major brands [4]. Financial Performance - For Q3 2024, the company achieved a revenue of 600 million yuan, a year-on-year increase of 25.79%, and a net profit of 62.27 million yuan, up 44.32% year-on-year [3]. - The average selling prices for various product categories increased, with skincare products seeing a notable price rise of 43.07% [4]. - The company expects EPS for 2024-2026 to be 0.89, 1.12, and 1.41 yuan, corresponding to PE ratios of 34, 27, and 21 times respectively [5]. Brand Performance - The eye care products generated 124 million yuan in revenue, up 22.28% year-on-year, while skincare products reached 215 million yuan, a 15.14% increase [4]. - The beauty product category saw a remarkable growth of 54.11% year-on-year, indicating a strong performance from the company's major brands [4]. Market Position - The company has established a differentiated positioning with its mid-to-high-end brand "Marubi" and the high-quality, minimalist makeup brand "Lianhuo" to meet diverse consumer needs [5].

| --- | --- | |--------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | 证券研究报告 | [Table_Title] 丸美股份 (603983.SH)24Q3 点评：持续推进大 | | 公司研究 | 单品策略，业绩延续亮 ...